Targetted medicine to reduce melanoma mutational burden

Bookmark and Share
Published: 22 Sep 2016
Views: 1141
Prof Grant McArthur - The Royal Melbourne Hospital, Melbourne, Australia

Prof McArthur speaks with ecancer at WCCS 2016 about targetted medicine to reduce melanoma mutational burden, with specific focus on the BRIM trials of cobimetinib and vemurafinib.

He outlines the expansion of personalised therapy and genotyping for improved duration and depth of response, considering the push from other quarters towards sequencing for all patients, and his hopes for the future of cancer vaccines.

However, Prof McArthur notes that these results do not indicate clinical readiness, and highlights brain metastases in melanoma as an area in need of further research.